RxDoctor Payments Data

Cindy Yueh, MD

Family Medicine · Brooklyn, NYNPI 1710206529

Payments from drug & device makers

$2,143in general payments, 2019–2025

Across 78 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$491
  • Welch Allyn$356
  • Amgen$296
  • Kowa Pharmaceuticals America, Inc.$178
  • Sanofi$162
  • AstraZeneca$152
  • plus $507 from 12 others

What the payments were for

  • Food & beverage$1,78783%
  • Gifts$35617%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,143 in reported general payments places this provider in the 75th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$82,595
Medicare patients
121
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$76,246
RybelsusSemaglutide12$27,745
TrulicityDulaglutide18$22,708
EliquisApixaban11$17,518
JanuviaSitagliptin Phosphate11$15,479
MounjaroTirzepatide11$11,006
Atorvastatin Calcium299$3,857
Levemir FlexpenInsulin Detemir18$2,607
SynthroidLevothyroxine Sodium21$1,716
Metoprolol Succinate89$1,503
Losartan Potassium111$1,326
Nifedipine ErNifedipine20$912
Metformin Hcl72$815
Ezetimibe23$814
Amlodipine Besylate160$793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$23$103,99152 claims
Lilly USA, LLCTrulicity, Mounjaro$33$33,71429 claims
PfizerEliquis$20$17,51811 claims
MerckJanuvia$18$15,47911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,321 family medicine providers in New York.

Other family medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →